What Lymph Nodes Does Ovarian Cancer Spread To?

Ovarian cancer spreads primarily to two groups of lymph nodes: the para-aortic nodes, which sit alongside the aorta in the upper abdomen, and the pelvic nodes, particularly those along the external iliac vessels and in the obturator fossa. These two regions account for the vast majority of lymph node involvement, but the story is more layered than a simple list of destinations. Which nodes are affected, how often, and what it means for treatment and prognosis all depend on the cancer’s subtype, stage, and the route the tumor cells take to get there.

The Two Main Drainage Pathways

The ovaries drain lymph through two principal routes. One follows the ovarian blood vessels upward through the infundibulopelvic ligament (the tissue that suspends the ovary) toward the para-aortic and paracaval lymph nodes, which cluster around the major blood vessels of the upper abdomen near the kidneys.¹ The second pathway runs along the uterine vessels downward into the pelvis, reaching the iliac lymph node compartments.² These two routes operate simultaneously, which means ovarian cancer cells can reach both pelvic and upper-abdominal nodes at the same time, rather than spreading step by step from one group to the next.

This dual-pathway anatomy matters clinically because it explains why surgeons cannot simply remove pelvic nodes and consider the job done. A tumor that looks confined to the pelvis may have already sent cells along the ovarian vessels to para-aortic nodes far above the pelvic rim. Conversely, a patient with clear para-aortic nodes might still have disease hiding in the pelvic basin.

Which Specific Node Groups Are Most Often Involved

Among the node regions surgeons remove, the para-aortic group is by far the most frequently positive. In a study of 110 patients who underwent both pelvic and aortic lymph node removal, the aortic group harbored metastases in about 83% of node-positive cases. The external iliac nodes were the next most common site at roughly 59%, followed by the obturator nodes at about 53%.³ Overall, about three-quarters of patients who had pelvic nodes removed in that series showed at least some nodal metastases, reflecting the advanced-stage population studied.

These numbers highlight a pattern that comes up again and again in the literature: the para-aortic nodes are the single most important nodal station in ovarian cancer. The pelvic nodes matter too, but if you could only check one region, the para-aortic area would catch the most disease.

Spread Above the Diaphragm

Ovarian cancer does not always stay below the diaphragm. When tumor cells ascend through the lymphatic chain, they can reach the cardiophrenic nodes (nestled where the diaphragm meets the heart), parasternal nodes, mediastinal nodes in the chest, and occasionally nodes in the neck or armpit. A PET/CT study of patients with advanced disease found that a meaningful proportion already had lymph node involvement above the diaphragm before treatment began, with the cardiophrenic and parasternal nodes being the most common supradiaphragmatic sites.⁴

In rarer cases, nodes in the neck, axilla, or mediastinum can become involved years after the original pelvic disease has been treated. One series documented women relapsing in cervical, mediastinal, or axillary nodes three to five years after achieving complete remission in the abdomen and pelvis, and two patients actually presented with lymph node disease above the diaphragm years before the primary ovarian tumor was even found.⁵ These cases are uncommon, but they illustrate that the lymphatic system connects all the way from the pelvis to the upper body, and ovarian cancer cells occasionally exploit the full highway.

Inguinal Nodes and Other Unusual Sites

The inguinal (groin) lymph nodes are not a typical destination for ovarian cancer. When tumor cells do show up there, researchers think the cells may travel along the round ligament of the uterus or follow the external iliac vessels downward. Another theory holds that inguinal involvement only occurs after the pelvic and para-aortic lymph node stations are essentially “full” or blocked by tumor, diverting flow to alternate routes.⁶ Inguinal node metastases from ovarian cancer remain rare enough to show up as individual case reports in the medical literature, which is itself a sign of how unusual they are.

Not All Ovarian Cancers Spread to Nodes at the Same Rate

The likelihood of lymph node involvement varies enormously depending on the tumor’s histological subtype. High-grade serous carcinoma, the most common and aggressive form, is by far the most prone to nodal spread. A review of early-stage disease found the serous subtype had the highest incidence of lymph node metastases at about 23%, while the mucinous subtype had the lowest at roughly 2.6%.⁷

A larger study examining both early and advanced disease confirmed this hierarchy. No lymph node metastases were found in patients with low-grade endometrioid carcinoma regardless of tumor stage. Early-stage mucinous tumors had zero nodal spread in 31 patients studied, and early-stage clear cell carcinoma showed only about a 4% rate. In contrast, more than 10% of patients with all other histological subtypes had positive nodes.⁸ This difference is clinically meaningful because it influences whether a surgeon recommends full lymph node removal or takes a more conservative approach. For a woman with an early-stage mucinous or low-grade endometrioid tumor, aggressive lymphadenectomy may offer little benefit relative to the risks.

Germ cell tumors of the ovary, which are biologically distinct from the much more common epithelial cancers, rarely spread to lymph nodes at all. In one study of 126 patients with clinically early-stage malignant germ cell tumors who underwent lymphadenectomy, only a single patient (0.8%) had nodal metastasis.⁹

How Lymph Nodes Fit Into Staging

The international staging system for ovarian cancer was recently updated, and lymph node involvement plays a specific role. When ovarian cancer has spread to retroperitoneal lymph nodes (the para-aortic and pelvic nodes behind the abdominal lining) without visible disease on the peritoneal surfaces inside the abdomen, it is classified as stage III. The 2025 update subdivides this further based on the size of the nodal metastasis: deposits 10 mm or smaller fall into one substage, while those larger than 10 mm fall into another.¹⁰ This distinction acknowledges what clinicians have long suspected: the volume of nodal disease matters for prognosis, not just whether nodes are positive or negative.

How Well Imaging Detects Nodal Spread

Detecting lymph node metastases before surgery is one of the more frustrating challenges in ovarian cancer management. Standard imaging is not great at finding small tumor deposits in normal-sized nodes. A meta-analysis comparing the main imaging tools found that PET or PET/CT was the most accurate, with a sensitivity of about 73% and specificity around 97%. CT scanning was less sensitive, catching only about 43% of involved nodes, and MRI fell in the middle at roughly 55% sensitivity.¹¹

A more recent study focused on advanced ovarian cancer painted an even more sobering picture for PET/CT in that population, finding a sensitivity of only about 27% for preoperative lymph node evaluation, although specificity remained high at roughly 91%.¹² What these numbers mean in plain terms is that imaging is good at confirming disease when it sees something abnormal, but it misses a substantial proportion of involved nodes, especially when the deposits are small. This gap is one reason surgical lymph node assessment remains important.

What Drives Lymph Node Spread at a Biological Level

Ovarian cancer cells do not passively drift into lymph nodes. The tumor actively promotes its own spread by producing a protein called VEGF-C, which stimulates the growth of new lymphatic vessels around the tumor, a process called lymphangiogenesis. Research has shown that tumors with higher VEGF-C expression develop more lymphatic vessels in their vicinity and are more likely to have lymph node metastases.¹³ In mouse models, VEGF-C directly induced new lymphatic vessel formation and increased nodal metastasis. This is not a passive process; the cancer essentially builds its own exit routes.

The Surgical Debate Over Lymph Node Removal

For years, the standard surgical approach to advanced ovarian cancer included systematic removal of pelvic and para-aortic lymph nodes during the initial debulking operation. The rationale seemed straightforward: if cancer spreads to nodes, take the nodes out. But a landmark randomized trial published in the New England Journal of Medicine challenged that logic. In patients with advanced ovarian cancer who had their visible tumor completely removed, adding systematic lymphadenectomy to the surgery did not improve survival. Median overall survival was about 69 months without lymphadenectomy and about 66 months with it, a difference that was not statistically meaningful. Progression-free survival was virtually identical at around 25.5 months in both groups.¹⁴

What the lymphadenectomy group did get was more complications. Rates of repeat surgery were roughly double, and death within 60 days of the operation was higher in the lymphadenectomy arm. This trial reshaped practice significantly: many centers now omit systematic lymphadenectomy in advanced-stage disease when all visible tumor has been removed, reserving node removal for situations where nodes are visibly enlarged or suspicious. In early-stage disease, lymph node assessment remains standard for accurate staging, because finding positive nodes can change the treatment plan.

Sentinel Lymph Node Mapping in Ovarian Cancer

The concept of sentinel node biopsy, well established in breast cancer and melanoma, is being actively tested in ovarian cancer. The idea is to identify and remove only the first few nodes that drain the tumor, sparing patients the morbidity of removing dozens of nodes. If the sentinel node is clean, the rest are likely clean too.

Results so far are promising but mixed. A prospective multicentre trial (SELLY) found that sentinel node detection worked in about 59% of patients with apparent early-stage ovarian cancer. Among those with successful mapping, about 15% had positive nodes, and the sentinel node correctly identified the disease in roughly 73% of those cases. Crucially though, about one in four patients with nodal disease had a negative sentinel node, meaning the technique missed their metastasis.¹⁵ That miss rate makes the approach not yet reliable enough for routine use.

Newer tracers may improve results. A trial using a hybrid tracer combining a radioactive marker with a fluorescent dye (indocyanine green) achieved a detection rate of over 92%, and among patients with malignant tumors, every positive sentinel node was correctly identified, with zero false negatives.¹⁶ These are early results from a small study, so they need to be confirmed in larger trials, but the direction is encouraging. If sentinel node biopsy can be made reliable in ovarian cancer, it would spare many women the complications of full lymphadenectomy while still catching the patients who genuinely need systemic treatment.

Micrometastases and Why They Matter

Standard pathology examination misses some lymph node involvement. When pathologists apply extra staining techniques, known as ultrastaging, they find tiny tumor deposits, called micrometastases or isolated tumor cells, that conventional methods overlook. One review noted that up to 40% of positive sentinel nodes contained deposits classified as micrometastases or isolated tumor cells that would have been missed without ultrastaging.¹⁷

The clinical importance of these tiny deposits is still being worked out. A large study (MICR-OVARY) of apparent early-stage ovarian cancer found that about 7% of patients had low-volume metastases in their sentinel nodes, split evenly between isolated tumor cells and micrometastases. Interestingly, patients with these low-volume deposits had excellent outcomes, with three-year disease-free survival of 100% and overall survival of 100%. This contrasted sharply with patients who had larger, visible metastases, whose three-year disease-free survival was only about 64%.¹⁸ These findings suggest that not all positive nodes are equal, and finding a few scattered tumor cells in a node may not carry the same grim implications as finding a large deposit.

Earlier research using p53 protein staining to detect micrometastases in early-stage patients found that those with micrometastasis had significantly worse prognosis, suggesting these tiny deposits may matter more for long-term outcomes even if short-term survival looks good.¹⁹ The discrepancy between these findings and the MICR-OVARY results likely reflects differences in study populations, detection methods, and follow-up duration. The field hasn’t yet settled on whether micrometastases should change treatment decisions.

When Ovarian Cancer Recurs in Lymph Nodes

Some women develop ovarian cancer recurrence exclusively in lymph nodes, without peritoneal or organ involvement. This pattern, called isolated lymph node recurrence, accounted for about 11% of recurrences in one series, and it carries a distinctly different prognosis from other recurrence patterns. Patients with isolated lymph node recurrence had a median post-relapse survival of about 37 months and median overall survival of about 109 months, with all patients surviving more than two years from their initial diagnosis. Roughly three-quarters remained free of peritoneal disease two years after the lymph node recurrence was found.²⁰

A systematic review of surgical treatment for this scenario concluded that secondary surgery to remove the involved nodes, combined with chemotherapy, can push post-relapse survival well beyond five years, with prolonged survival exceeding 110 months being a realistic target for a meaningful proportion of these patients.²¹ The key caveat is that once peritoneal spreading develops after a lymph node recurrence, the outlook worsens rapidly. So identifying and treating isolated lymph node recurrences early, before peritoneal disease sets in, matters.

Lymph Node Status After Neoadjuvant Chemotherapy

Some patients with advanced ovarian cancer receive chemotherapy before surgery (neoadjuvant chemotherapy) to shrink the tumor and make the operation more feasible. The status of lymph nodes after this chemotherapy has prognostic meaning. In a retrospective study, patients who still had visible lymph node metastases at the time of surgery after neoadjuvant chemotherapy had notably worse outcomes: their median progression-free survival was about 21 months, compared with roughly 32 months for patients without visible nodal disease. The time to platinum resistance was also significantly shorter.²² Persistent lymph node enlargement after chemotherapy, in other words, is a signal that the disease is more resistant and may need closer monitoring or different treatment strategies.

Lower Limb Lymphedema After Node Removal

Removing lymph nodes is not without lasting consequences. Lower limb lymphedema, a chronic swelling of the legs caused by disrupted lymphatic drainage, is a well-known complication of pelvic and para-aortic lymphadenectomy. A five-year prospective study found a cumulative incidence of about 40%, with the highest rates in the first year after surgery. Patients who received taxane-based chemotherapy (a common regimen for ovarian cancer) or had 60 or more nodes removed faced even higher rates, approaching 50%.²³ Post-operative radiotherapy, while less common in ovarian cancer than in uterine cancers, also increases risk.²⁴

These figures underscore why the shift away from routine lymphadenectomy in advanced disease has been welcomed by many clinicians. When removing nodes does not improve survival but does cause chronic swelling in roughly two out of five patients, the calculus is clear. For early-stage disease, where nodal status genuinely changes the treatment plan, the tradeoff may still be worth it, but surgeons are increasingly exploring sentinel node approaches to minimize the number of nodes removed and, with it, the risk of lymphedema.

Do BRCA Mutations Predict Lymph Node Spread

BRCA1 and BRCA2 mutations are among the most well-known genetic risk factors for ovarian cancer, so it is natural to wonder whether they also predict where and how aggressively the cancer spreads to lymph nodes. Research combining tumor markers with BRCA mutation status showed promise for predicting lymph node involvement as part of a broader diagnostic panel.²⁵ However, when BRCA mutation status was examined on its own as a predictor of lymph node involvement in advanced-stage disease, no significant correlation was found.²⁶ In practical terms, having a BRCA mutation does not appear to make lymph node spread any more or less likely in advanced disease, even though it affects many other aspects of treatment, including eligibility for targeted therapies like PARP inhibitors.